17/10/2024 – AB Science today announces that the European Medicines Agency (EMA) confirmed a negative opinion for the conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis Download PDF Post navigationPreviousPrevious post:Revenues for the first half of 2024 and update on AB Science’s activitiesNextNext post:AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell diseaseRelated PostsSummary of the webcast held on January 28, 202529 January 2025Summary of the webcast held on December 16, 202417 December 2024AB Science webcast of December 16, 202416 December 2024Live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET11 December 2024AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease28 October 2024Revenues for the first half of 2024 and update on AB Science’s activities10 October 2024
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease28 October 2024
